Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells
Leucid will work with Lonza on the Cocoon® Platform for Leucid Bio’s Phase I/II clinical studies with its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer Leucid will utilise the Cocoon® Platform through to commercial manufacturing. London, UK – 2 December 2021 – Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering […]
